ArticleTranslational gastroenterology and hepatology2026
A mechanism-derived four-gene prognostic signature for hepatocellular carcinoma based on the multi-target anti-tumor activity of icaritin.
Article in Translational gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To systematically dissect the multi-target molecular mechanisms of icaritin against hepatocellular carcinoma (HCC) and construct a mechanism-based gene prognostic signature for HCC risk stratification, aiming to provide a translational tool for individualized risk assessment. Methods: Transcriptomic profiles and clinical data from The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC) cohort, icaritin potential targets, and HCC pathogenic genes were integrated for Venn intersection screening. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment and protein-protein interaction (PPI) network analyses were performed. Univariate Cox regression followed by least absolute shrinkage and selection operator (LASSO) penalized Cox regression was applied to eliminate multicollinearity and screen stable prognostic genes. The signature's predictive performance was validated via Kaplan-Meier survival curves, time-dependent receiver operating characteristic (ROC) curves, and multivariate Cox regression in TCGA and independent Gene Expression Omnibus (GEO) external cohorts. Results: A total of 37 intersecting genes linking icaritin to HCC progression were identified, enriched in cell cycle regulation, oxidative stress metabolism, and p53 signaling pathways. After LASSO regularization to resolve severe multicollinearity between Conclusions: This study systematically elucidates the synergistic multi-pathway anti-HCC mechanisms of icaritin and constructs a statistically robust four-gene prognostic signature. The signature provides a translational tool for individualized HCC risk evaluation and offers candidate biomarkers for subsequent preclinical validation of icaritin therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.